Background
Cancer-associated venous thromboembolism (VTE), comprising pulmonary embolism (PE) and deep vein thrombosis (DVT), represents a significant contributor to morbidity and mortality among patients with active malignancy. As cancer incidence rises alongside improved cancer survival, managing thrombotic complications has become increasingly critical. While anticoagulants remain the mainstay for VTE treatment, adjuvant therapies aiming to reduce VTE recurrence and mortality are actively investigated. Aspirin, renowned for its antiplatelet effects, is widely used for primary thromboprophylaxis in cancer subpopulations and has shown anticancer properties in various studies. However, its efficacy and safety when used adjunctively with anticoagulants in treating established cancer-associated VTE remain unclear. This retrospective multicenter study was undertaken to elucidate the role of low-dose aspirin as an adjuvant therapy in this high-risk context.
